Takeda has signed a multi-target agreement with biotech HiFiBiO Therapeutics to enable the discovery of antibody therapies to potentially treat various gastrointestinal diseases, cancers and other disorders.
According to the agreement, scientists from both companies will work together to discover antibodies against Takeda’s targets using HiFiBiO Therapeutics’ single-cell screening capabilities. Takeda will be responsible for the preclinical and clinical development of the discovered antibodies.
HiFiBiO Therapeutics will receive upfront, R&D, milestone, and royalty payments based on antibodies delivered to Takeda for development and commercialisation. Specific financial terms of the transaction were not disclosed.
“Takeda is a world leader in oncology, gastroenterology and neuroscience therapeutics,” said Liang Schweizer, president and CEO of HiFiBiO. “This multi-target partnership further validates our ongoing commitment to these types of open-innovation collaborations to better address unmet medical needs around the world.”